MarketInOut Stock Screener Log In | Sign Up

Mesoblast Ltd ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 11/20/2026
Mesoblast Ltd ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,511.51 mln
Float94.94 mln
Earnings Date03/04/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

2
Highly suspicious

Relative Strength

15 / 100
Significantly lagging

Debt / Equity

0.22
Very low leverage

Pre-Tax Margin

-48%
Deeply loss-making

ROE

-9.94
Negative

Business Description

Mesoblast is an Australian biotech company founded in 2004 that develops cell-based therapies to treat serious inflammatory and degenerative conditions across multiple countries. Its work centers on a specialized cell technology used to create treatments for conditions such as graft versus host disease, heart failure, inflammatory bowel disease, and chronic back pain. The company has formed partnerships with pharmaceutical firms including Tasly, JCR Pharmaceuticals, and Grünenthal to bring several of these therapies to patients around the world.

Key Fundamentals

EPS-0.44
ROE-9.94
RPS0.93
ROIC-7.81
ROA-7.40
EBITDA, mln-24.51
EV / EBITDA-66.35
EV / EBIT-49.40
Revenue, mln121
EV / Revenue13.88

Quote Details

Last 10.89
Change -0.29 (-2.59%)
Open 11.19
Volume 192,703
Turnover 2,098,536
Average Volume 226,595

Financial Ratios

Pre-Tax Profit Margin-48
Leverage Ratio1.36
Current Ratio2.44
Price / Book2.93
Debt / Equity0.22
Price / Sales13.54

Financial Strength

Altman Z-Score3.16
Piotroski F-Score 4 / 9
Beneish M-Score2
Short Ratio11.91
Short % of Float3.77

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -17.94% 19 / 100   
1 Month -13.23% 36 / 100   
2 Months -36.02% 24 / 100   
6 Months -28.36% 29 / 100   
1 Year -26.67% 29 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog